SMT201600022B - Pirrolobenzodiazepine e loro coniugati - Google Patents

Pirrolobenzodiazepine e loro coniugati

Info

Publication number
SMT201600022B
SMT201600022B SM201600022T SM201600022T SMT201600022B SM T201600022 B SMT201600022 B SM T201600022B SM 201600022 T SM201600022 T SM 201600022T SM 201600022 T SM201600022 T SM 201600022T SM T201600022 B SMT201600022 B SM T201600022B
Authority
SM
San Marino
Prior art keywords
pirrolobenzodiazepine
conjugates
Prior art date
Application number
SM201600022T
Other languages
English (en)
Inventor
John A Flygare
Janet L Gunzner-Toste
Thomas Pillow
Philip Wilson Howard
Luke Masterson
Original Assignee
Medimmune Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161547187P priority Critical
Priority to PCT/US2012/059864 priority patent/WO2013055987A1/en
Application filed by Medimmune Ltd, Genentech Inc filed Critical Medimmune Ltd
Publication of SMT201600022B publication Critical patent/SMT201600022B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1,4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1,4 condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
SM201600022T 2011-10-14 2016-01-21 Pirrolobenzodiazepine e loro coniugati SMT201600022B (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201161547187P true 2011-10-14 2011-10-14
PCT/US2012/059864 WO2013055987A1 (en) 2011-10-14 2012-10-12 Pyrrolobenzodiazepines and conjugates thereof

Publications (1)

Publication Number Publication Date
SMT201600022B true SMT201600022B (it) 2016-02-25

Family

ID=47116426

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600022T SMT201600022B (it) 2011-10-14 2016-01-21 Pirrolobenzodiazepine e loro coniugati

Country Status (26)

Country Link
US (1) US20130266595A1 (it)
EP (1) EP2750713B1 (it)
JP (1) JP6104257B2 (it)
KR (1) KR101877598B1 (it)
CN (1) CN103987407B (it)
AU (1) AU2012322607B2 (it)
BR (1) BR112014009050A2 (it)
CA (1) CA2850371A1 (it)
CY (1) CY1117048T1 (it)
DK (1) DK2750713T3 (it)
EA (1) EA026827B1 (it)
ES (1) ES2556584T3 (it)
HK (1) HK1195017A1 (it)
HR (1) HRP20151374T1 (it)
HU (1) HUE025661T2 (it)
IL (1) IL231796A (it)
MX (1) MX350152B (it)
NZ (1) NZ623209A (it)
PL (1) PL2750713T3 (it)
PT (1) PT2750713E (it)
RS (1) RS54446B1 (it)
SG (1) SG11201401406YA (it)
SI (1) SI2750713T1 (it)
SM (1) SMT201600022B (it)
WO (1) WO2013055987A1 (it)
ZA (1) ZA201402275B (it)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
AU2011239522B2 (en) 2010-04-15 2014-10-23 Medimmune Limited Targeted pyrrolobenzodiazapine conjugates
EP3296321B1 (en) 2010-12-20 2020-07-15 F. Hoffmann-La Roche AG Anti-mesothelin antibodies and immunoconjugates
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc ANTI-KIT ANTIBODIES AND THEIR USES
CN103987718A (zh) 2011-09-20 2014-08-13 斯皮罗根有限公司 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
WO2013055990A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
EP3309162A1 (en) 2011-10-14 2018-04-18 Seattle Genetics, Inc. Targeted conjugates of pyrrolobenzodiazepines
US9388187B2 (en) 2011-10-14 2016-07-12 Medimmune Limited Pyrrolobenzodiazepines
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
JP2015528818A (ja) * 2012-08-02 2015-10-01 ジェネンテック, インコーポレイテッド 抗etbr抗体およびイムノコンジュゲート
PT2906251T (pt) * 2012-10-12 2017-12-04 Medimmune Ltd CONJUGATES OF PYRROLOBENZODIAZEPINA-ANTIBODY ANTI-CD22
BR112015008251A2 (pt) 2012-10-12 2017-07-04 Spirogen Sarl pirrolobenzodiazepinas e conjugados destas
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2014057118A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
US9745303B2 (en) 2012-10-12 2017-08-29 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
AU2013328621B2 (en) * 2012-10-12 2016-12-01 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-HER2 antibody conjugates
PL2906298T3 (pl) 2012-10-12 2019-04-30 Adc Therapeutics Sa Pyrrolobenzodiazepine conjugates - antibody
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
JP6270859B2 (ja) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルAdc Therapeutics Sarl ピロロベンゾジアゼピン−抗体結合体
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
LT2958944T (lt) 2013-02-22 2019-07-10 Abbvie Stemcentrx Llc Antikūno prieš dll3 ir pbd konjugatai bei jų panaudojimas
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
JP2017503010A (ja) 2013-12-16 2017-01-26 ジェネンテック, インコーポレイテッド 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
EA201690195A1 (ru) 2013-08-12 2016-05-31 Дженентек, Инк. Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス, インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
CA2922889A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
JP2017500028A (ja) * 2013-12-12 2017-01-05 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗dpep3抗体および使用方法
EA033456B1 (ru) 2013-12-16 2019-10-31 Genentech Inc Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры
WO2015112822A1 (en) * 2014-01-24 2015-07-30 Kolltan Pharmaceuticals, Inc. Antibody-drug conjugates targeting kit receptor and uses thereof
CA2939941A1 (en) 2014-02-21 2015-08-27 Abbvie Stemcentrx Llc Anti-dll3 antibodies and drug conjugates for use in melanoma
CN106659782A (zh) 2014-05-23 2017-05-10 科尔坦制药公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20170066421A (ko) 2014-09-12 2017-06-14 제넨테크, 인크. 항-cll-1 항체 및 면역접합체
JP2017534253A (ja) 2014-09-12 2017-11-24 ジェネンテック, インコーポレイテッド Anti-HER2 antibody and immune complex
RU2017112884A3 (it) 2014-09-17 2019-04-29
CR20170099A (es) * 2014-09-17 2017-07-19 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
CA2968447A1 (en) 2014-11-25 2016-06-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP3333191B1 (en) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
CA2973355A1 (en) 2015-01-14 2016-07-21 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
EA201791550A1 (ru) 2015-01-14 2017-11-30 Бристол-Маерс Сквибб Компани Димеры бензодиазепинов, их конъюгаты и способы их получения и применения
CN107847568A (zh) 2015-06-16 2018-03-27 豪夫迈·罗氏有限公司 抗cll‑1抗体和使用方法
KR20180019592A (ko) 2015-06-23 2018-02-26 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 벤조디아제핀 이량체, 그의 접합체, 제조법 및 용도
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
JP6621919B2 (ja) 2015-10-16 2019-12-18 ジェネンテック, インコーポレイテッド 束縛ジスルフィド薬物コンジュゲート
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458069A2 (en) 2016-05-18 2019-03-27 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
JP2019522660A (ja) 2016-06-24 2019-08-15 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピンおよびその結合体
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
BR112019021880A2 (pt) 2017-04-20 2020-06-02 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo anti-axl-droga
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
TW201929908A (zh) 2017-12-21 2019-08-01 美商梅爾莎納醫療公司 Pyrrolobenzoquinone antibody conjugate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818731D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CN101065151B (zh) * 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
ES2374964T3 (es) * 2006-01-25 2012-02-23 Sanofi Agentes citotóxicos que comprenden nuevos derivados de tomaimicina.
US7776363B2 (en) * 2006-01-27 2010-08-17 Nalco Company Suppressing microbial growth in pulp and paper
DK2528625T3 (da) * 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf

Also Published As

Publication number Publication date
HRP20151374T1 (en) 2016-01-15
EA026827B1 (ru) 2017-05-31
PL2750713T3 (pl) 2016-03-31
AU2012322607B2 (en) 2017-02-16
HUE025661T2 (en) 2016-04-28
ES2556584T3 (es) 2016-01-19
JP2014534199A (ja) 2014-12-18
DK2750713T3 (en) 2015-12-21
HK1195017A1 (zh) 2014-10-31
US20130266595A1 (en) 2013-10-10
EA201490580A1 (ru) 2014-11-28
JP6104257B2 (ja) 2017-03-29
AU2012322607A1 (en) 2014-05-29
KR20140078735A (ko) 2014-06-25
KR101877598B1 (ko) 2018-07-11
CA2850371A1 (en) 2013-04-18
CY1117048T1 (el) 2017-04-05
CN103987407A (zh) 2014-08-13
NZ623209A (en) 2015-11-27
MX350152B (es) 2017-08-29
IL231796A (en) 2017-05-29
PT2750713E (pt) 2016-01-20
MX2014004434A (es) 2014-09-22
RS54446B1 (en) 2016-06-30
ZA201402275B (en) 2015-11-25
CN103987407B (zh) 2016-08-24
WO2013055987A1 (en) 2013-04-18
BR112014009050A2 (pt) 2018-12-04
SG11201401406YA (en) 2014-05-29
SI2750713T1 (sl) 2016-01-29
IL231796D0 (en) 2014-05-28
EP2750713A1 (en) 2014-07-09
EP2750713B1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
NO2019006I1 (no) Tisagenlekleucel
NO2019020I1 (no) lanadelumab
NO2019038I1 (no) Risankizumab
CO6801645A2 (es) Nuevos inmunoconjugados
SMT201500291B (it) Nuovi agenti antimalarici
NO2019022I1 (no) Natriumzirkoniumsyklosilikat
SMT201600400B (it) Inalatore
NO2018039I1 (no) Rukaparibkamsylat
SMT201600298B (it) Derivati n3-sostituiti-n1-solfonil-5- fluoropirimidinone
CO6811812A2 (es) Anticuerpo anti-b7-h3
ITBO20110672A1 (it) Sigaretta elettronica
SMT201500072B (it) Pyrrolobenzodiazepines and their conjugates
CR20130111A (es) Triazina-oxidiazoles
NO2017034I1 (no) Idarucizumab
NO2010019I2 (no) 6-per-deoxy-6-per- (2-karboksetyl) thio-y-cyclodextrin
SMT201600022B (it) Pirrolobenzodiazepine e loro coniugati
ITVI20100321A1 (it) Bottiglia
NO20131470A1 (no) Bropluggverktøy
NO20120395A1 (no) Stromningsstyringssystem
NO20100814A1 (no) Tynnkompositter
CO6960543A2 (es) 2-tiopirimidinonas
NO20110970A1 (no) Oppbygget flenslasedeksel
SMT201500078B (it) Fellosilicato modificato
CO6791565A2 (es) Anticuerpos anti-notch1
IT1404805B1 (it) Disperdenti